Veru

-$0.10 (-1.43%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Veru and other ETFs, options, and stocks.

About VERU

Veru, Inc. is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

CEO
Mitchell Shuster Steiner
Employees
339
Headquarters
Miami, Florida
Founded
1996

VERU Key Statistics

Market Cap
710.00M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
697.00K
High Today
$7.02
Low Today
$6.84
Open Price
$6.88
Volume
412.94K
52 Week High
$24.57
52 Week Low
$2.30

VERU Earnings

-$0.06
-$0.03
$0.00
$0.03
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Available Aug 12, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure